PA
NVCR icon

Parallel Advisors’s NovoCure NVCR Stock Holding History

Parallel Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62K Buy
240
+111
+86% +$1.39K ﹤0.01% 3283
2025
Q4 		$1.67K Sell
129
-296
-70% -$3.8K ﹤0.01% 3176
2025
Q3 		$5.49K Sell
425
-1,169
-73% -$15.6K ﹤0.01% 2743
2025
Q2 		$28.4K Sell
1,594
-324
-17% -$5.65K ﹤0.01% 2028
2025
Q1 		$34.2K Buy
1,918
+100
+6% +$2.27K ﹤0.01% 1863
2024
Q4 		$54.2K Buy
1,818
+27
+2% +$571 ﹤0.01% 1591
2024
Q3 		$28K Sell
1,791
-72
-4% -$1.31K ﹤0.01% 1898
2024
Q2 		$31.9K Buy
1,863
+487
+35% +$8.56K ﹤0.01% 1743
2024
Q1 		$21.5K Buy
1,376
+1,109
+415% +$16.3K ﹤0.01% 1938
2023
Q4 		$3.99K Buy
267
+28
+12% +$375 ﹤0.01% 2586
2023
Q3 		$3.86K Buy
239
+223
+1,394% +$6.43K ﹤0.01% 2592
2023
Q2 		$664 Sell
16
-148
-90% -$9.19K ﹤0.01% 3037
2023
Q1 		$9.86K Sell
164
-346
-68% -$27.6K ﹤0.01% 2135
2022
Q4 		$37.4K Buy
510
+24
+5% +$1.81K ﹤0.01% 1410
2022
Q3 		$37K Sell
486
-66
-12% -$5.15K ﹤0.01% 1397
2022
Q2 		$38K Sell
552
-121
-18% -$9.12K ﹤0.01% 1386
2022
Q1 		$57K Buy
673
+226
+51% +$16.6K ﹤0.01% 1229
2021
Q4 		$34K Buy
447
+294
+192% +$29.5K ﹤0.01% 1538
2021
Q3 		$18K Sell
153
-6
-4% -$907 ﹤0.01% 1797
2021
Q2 		$35K Buy
159
+91
+134% +$17.7K ﹤0.01% 1417
2021
Q1 		$9K Buy
68
+16
+31% +$2.53K ﹤0.01% 1972
2020
Q4 		$9K Buy
+52
New +$7.12K ﹤0.01% 1833
2020
Q2 		– Sell
-3
Closed – – 2623
2020
Q1 		$0 Buy
+3
New +$237 ﹤0.01% 2562

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Parallel Advisors's NVCR Position: Q1 2026 in Review

Parallel Advisors increased its NovoCure (NVCR) stake by 86% in Q1 2026, buying an estimated $1.39K and bringing the position to 240 shares worth $2.62K. The position accounts for ﹤0.01% of the portfolio, ranked #3283.

Parallel Advisors first reported a position in NVCR in Q1 2020 and has held it in 23 quarters since. The position peaked at $57K in Q1 2022. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Parallel Advisors held 240 shares of NovoCure worth $2.62K as of Q1 2026.
  • Parallel Advisors bought 111 NovoCure shares in Q1 2026, an estimated $1.39K.
  • NovoCure made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3283 holding.
  • Parallel Advisors first reported a position in NovoCure in Q1 2020 and has held it in 23 quarters since.
  • Parallel Advisors's NovoCure position peaked at $57K in Q1 2022.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.